On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On February 13, 2024, the U.S. Food and Drug Administration granted approval for the use of irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) as a combined treatment
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On December 13, 2023, the U.S. Food and Drug Administration granted approval to eflornithine (IWILFIN, USWM, LLC) for adult and pediatric patients with high-risk neuroblastoma (HRNB)
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The U.S. Food and Drug Administration gave its approval for the use of enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) as a
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On December 14, 2023, the U.S. Food and Drug Administration granted approval to belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 16, 2023, the U.S. Food and Drug Administration approved Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy as the first line treatment for adults with
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On the date of approval, the U.S. Food and Drug Administration approved Nirogacestat (Ogsiveo) for adult patients with progressing desmoid tumors who require systemic treatment. This
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 16, 2023, the U.S. Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with Fulvestrant for adult patients with hormone receptor
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The U.S. Food and Drug Administration granted accelerated approval for Pirtobrutinib (Jaypirca) to be administered to adult patients diagnosed with chronic lymphocytic leukemia (CLL) or small
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 8, 2023, the U.S. Food and Drug Administration granted approval to Fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for adult patients who have metastatic colorectal cancer
More
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On October 27, the U.S. Food and Drug Administration approved toripalimab-tpzi (Loqtorzi) in combination with chemotherapy for adult patients with metastatic or locally advanced nasopharyngeal carcinoma
More